Chronic intrathecal bupivacaine: the systemic levels are low, and the flow rate matters

Design

Single-centre retrospective observational study with serial serum assays

Population

31 patients on chronic intrathecal bupivacaine for refractory cancer pain; 162 blood samples

Primary outcome

Serum bupivacaine concentration and its determinants

Effect

Mean daily dose 39.5 mg (SD 31.4) gave mean serum 167.7 micrograms/L (SD 266.2) against a 2000 micrograms/L toxicity threshold; flow rate independently associated with higher levels after adjustment for dose

Intrathecal bupivacaine for refractory cancer pain is often escalated to daily doses that would be frankly dangerous by any other route, and the usual reassurance — that intrathecal drug stays intrathecal — has been assumption rather than measurement. This single-centre retrospective study measured it. Thirty-one patients with implanted pumps gave 162 blood samples, taken before each pump refill.

The mean daily intrathecal bupivacaine dose was 39.5 mg (SD 31.4), and the mean serum concentration was 167.7 micrograms per litre (SD 266.2). The accepted systemic toxicity threshold is 2000 micrograms per litre, so the average patient sat at under a tenth of it. Serum levels rose with daily dose, as expected, and were influenced by body mass index. The finding worth carrying is the third one: after adjusting for daily dose, a higher infusion flow rate was independently associated with higher serum concentrations.

That last point has a practical edge. Flow rate and daily dose are separable settings — the same milligrams can be delivered in a larger volume at a faster rate or a smaller volume slowly — and this suggests the faster delivery pushes more drug into the systemic circulation for the same dose. If you are troubleshooting a patient with systemic symptoms on intrathecal therapy, or planning a large flow increase to widen dermatomal spread, the flow rate is a variable to think about rather than a purely mechanical setting.

• Reassure patients and referrers that measured systemic bupivacaine on chronic intrathecal therapy sits far below the toxicity threshold.
• Consider flow rate, not only daily dose, when a patient develops unexplained systemic symptoms.
• Note the wide spread: individual patients ran far above the mean, so a level is worth measuring if symptoms are unexplained.
• Record concentration, daily dose and flow rate together at every refill so changes are attributable.

Why it matters

It replaces an assumption about intrathecal safety with a measured number, and finds a variable nobody was watching.

Don't overread it

Observational and single-centre — this cannot show that lowering flow rate reduces systemic exposure.

The statistics, in plain English

A mean of 167.7 micrograms per litre with a standard deviation of 266.2 is the number to pause on: the spread is larger than the average, which means the distribution is heavily skewed and some patients were far higher than the mean suggests. Reporting reassurance from the mean alone would be misleading. A retrospective observational design also cannot separate cause from confounding — patients on higher flow rates are likely to differ in ways beyond flow rate, including disease burden and body habitus.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.